Literature DB >> 8636739

Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.

S E Lipshultz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8636739     DOI： 10.1200/JCO.1996.14.2.328

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

Review 1.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Authors:  Douglas B Sawyer; Xuyang Peng; Billy Chen; Laura Pentassuglia; Chee Chew Lim
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

2.  [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].

Authors:  H Sauer
Journal:  Strahlenther Onkol       Date:  1997-01       Impact factor: 3.621

Review 3.  Cardiovascular disease in adult survivors of childhood cancer.

Authors:  Steven E Lipshultz; Vivian I Franco; Tracie L Miller; Steven D Colan; Stephen E Sallan
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 4.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

Review 5.  Cardiotoxicity of cancer chemotherapy: implications for children.

Authors:  Valeriano C Simbre; Sarah A Duffy; Gul H Dadlani; Tracie L Miller; Steven E Lipshultz
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

6.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

Review 7.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Authors:  Jean Domercant; Nichole Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2016

Review 9.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.

Authors:  Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-12       Impact factor: 4.733
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.